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Summary The immunohistochemical expression of p53 protein (p53) was examined in 52 patients out of a
series of 66 patients with low-grade astrocytomas with long-term follow-up. All patients were also evaluated
for several clinical and histological features, among which only preoperative Karnofsky score and the extent of
surgery were statistically significant parameters to predict outcome on multivariate analysis. p53 accumulation
was seen in 46.1% of patients, with a wide range of percentage of positive cells. Median survival for
p53-positive and p53-negative patients was 41 and 37 months respectively. The survival curves of p53-positive
and -negative patients were not statistically different. However, the curves showed a trend towards a more
a'ggressive course in p53-positive patients beginning 3-4 years after surgery. Five years after diagnosis the
survival estimate with the Kaplan-Meier method was 21.2% for patients with p53-positive tumours and
45.9% for patients with p53-negative tumours. This trend is not due to different distribution of major clinical
prognostic factors (age, incomplete resection or Karnofsky status). The trend could be related to the time
needed by the p53-positive clone to outgrow the rest of the p53-negative neoplastic cell population. This
hypothesis is further supported by the fact that the five recurrences which were surgically removed (one
anaplastic astrocytoma and four glioblastomas) derived from p53-positive tumours and were themselves
intensely p53 positive.
Low-grade astrocytomas are differentiated from the much
more aggressive anaplastic astrocytomas and glioblastomas
because they behave quite differently and are associated with
a much better prognosis. Nevertheless, some low-grade astro-
cytomas progress rapidly and carry a poor prognosis. Several
studies have tested the association of clinical and histological
features of astrocytic tumours with clinical behaviour
(Daumas-Duport et al., 1988; Schiffer et al., 1988; Burger,
1990).
In low-grade astrocytomas the classical histological
features alone have only limited value in predicting outcome
(Soffietti et al., 1989): therefore additional biological
parameters which could improve prognostication have been
intensely investigated. Among these parameters are the pro-
liferative activity (Burger et al., 1986; Giangaspero et al.,
1987; Hoshino et al., 1988; Allegranza et al., 1991; Jaros et
al., 1992), DNA content (Nishizaki et al., 1989) and altera-
tions of oncogenes and tumour-suppressor genes (Baugnet-
Mahieu et al., 1990; Venter & Thomas, 1991; Orian et al.,
1992; Jaros et al., 1992; Haapasalo et al., 1993).
The investigated tumour-suppressor genes include the p53
gene and its product, which have key functions in regulating
cell proliferation (Mercer et al., 1990), differentiation (Kastan
et al., 1991a), DNA repair (Kastan et al., 1991b; Lane, 1992)
cell senescence and apoptosis (Shay et al., 1991; Yonish-
Rouach et al., 1991; Lane, 1992). The p53 product is a
nuclear phosphoprotein with short half-life and low nuclear
concentration. In most normal tissues, the p53 protein (p53)
nuclear concentration is below the threshold of detection of
the usual immunohistochemical methods. Somatic mutations
of the p53 gene are frequent genetic lesions in human neo-
plasms and the mutated p53 protein is usually more meta-
bolically stable than the wild-type protein and accumulates in
the nucleus (Finlay et al., 1989), where it can be demon-
strated by immunohistochemistry (Iggo et al., 1990).
Altered expression of p53 has been associated with aggres-
sive clinical behaviour in breast (Thor et al., 1992), prostate
(Visakorpi et al., 1992) and colon tumours (Sun et al.,
1992).
In brain tumours, p53 gene mutation and p53 protein
accumulation have been documented in few cases of low-
grade astrocytomas (Sidransky et al., 1990; Barbareschi et al.,
1992a; Ellison et al., 1992; von Deimling et al., 1992, 1993),
are more frequent in high-grade tumours (Chung et al., 1991;
Barbareschi et al., 1992a; Ellison et al., 1992; Jaros et al.,
1992) and are associated with tumour progression (Hayashi
et al., 1991; Ellison et al., 1992; Sidransky et al., 1992;
Karamitopouluo et al., 1993).
The possible role of p53 overaccumulation as a prognostic
factor in brain tumours has been suggested by Jaros et al.
(1992). In their series of low- and high-grade astrocytomas,
p53 overexpression was associated with reduced survival.
However, their number of low-grade tumours was too small
to attempt a separate survival analysis. In the present study
we investigated a series of 52 low-grade astrocytomas (grade
II according to the World Health Organization; Kleihues et
al., 1993) to evaluate the relations between p53 protein
overaccumulation and survival.
Materials and methods
Surgically resected specimens of 66 grade II human ast-
rocytomas and five recurrences of the above cases were in-
vestigated. The series of primary tumours included 64
astrocytomas and two pleomorphic xanthoastrocytomas.
Small biopsies were excluded because of the frequent hetero-
geneity of the histopathological features in different tumour
areas. The mean age of the patients was 37.4 years (range
16-74 years). All primary tumours were supratentorial (13
frontal, ten parietal, five of the rolandic region, 19 temporal,
six in the basal ganglia and 13 in the corpus callosum). The
tumours were fixed in 10% buffered formalin for 24h and
subsequently processed with routine techniques and paraffin
embedded. All the patients were operated on at the Depart-
ment of Neurosurgery of the Ospedale Civile Maggiore of
Verona between 1977 and 1988. Forty-eight were followed
until death and 18 were alive after a median follow-up period
of 73.5 months (mean 84.7, range 40-141).
All patients were evaluated for the following clinical,
therapeutical and histological parameters: age, sex, duration
of symptoms, neurological deficit on admission, pre- and
post-operative performance status, time from diagnosis to
treatment, extent of surgery, radiotherapy, cellular density,
nuclear pleomorphism, mitotic activity, vessels, endothelial
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hyperplasia, microcysts, and microcalcifications. Performance
status was evaluated with the Karnofsky score system, which
is based on the presence or absence of clinical signs of the
disease (high score, from 100 to 80), the inability to do
normal activity or the requirement for frequent medical care
(medium score, from 70 to 50), and the need for special care
or hospitalisation (low score, from 40 to 10) (Karnofsky &
Burchenl, 1949). Cellular density was scored as low [<400
cells per high-power field (HPF)] and moderate (400-800
cells per HPF). High-grade nuclear polymorphism was seen
only in two pleomorphic xanthoastrocytomas; among the
other- tumours nuclear pleomorphism was graded as slight
(31 cases) and moderate (33 cases). Mitotic figures were
either absent or extremely rare. Vessels were scored as nor-
mal iftheir density was similar to the density ofvessels in the
normal brain tissue, and as increased if their density was
higher than in normal brain. Endothelial hyperplasia was
never seen in primary low-grade astrocytomas.
Fourteen primary tumours were not suitable for
immunohistochemical evaluation because offixation artifacts.
Of the remaining 52 primary tumours, 20 were classified as
fibrillary astrocytomas, 32 as protoplasmic astrocytomas and
two as pleomorphic xanthoastrocytomas. Their five recur-
rences showed features of high-grade astrocytic tumours
(four glioblastoma multiforme and one anaplastic astro-
cytoma). Median survival of the 52 patients was 38.5
months.
p53 immunoreactivity was evaluated with the monoclonal
antibody (MAb) D07 (Vojtesec et al., 1992) as previously
described (Dei Tos et al., 1993). The antibody recognises an
epitope of the human wild-type p53 protein between amino
acids 1 and 45. Briefly, 4-itm-thick sections were cut from
paraffin blocks and rehydrated. Endogenous peroxidase was
blocked and the sections were incubated with normal non-
immune horse serum for 20 min at room temperature. The
sections were then incubated for 2 h at room temperature
with the primary antibody at 1:200 dilution; biotinylated
horse anti-mouse IgG at 1:200 dilution and avidin-biotin-
peroxidase complex (ABC) at 1:100 dilution were added in
sequence (Vectastain ABC Kit, Vector). Negative controls
were obtained omitting the primary antibody; positive con-
trols were sections oflung and laryngeal neoplasms known to
express p53 or to bear p53 gene mutations (Barbareschi et
al., 1992b; Maestro et al., 1992).
In all p53-immunoreactive cases the staining was quantified
on an Olympus BH2 microscope at 400 x using a square
graticule. One thousand nuclei were counted in each case,
and the percentage of p53-positive nuclei was recorded as the
p53 labelling index (pS3LI). When regional heterogeneity of
labelling was detected in the tumour, counting areas were
chosen to include those with higher density of p53-positive
cells. Tumours were considered p53 positive if more than 1%
of the cells showed nuclear staining.
Statistical analysis was performed using the SAS System
(PROC LIFETEST and PROC PHREG) run on an HP
Vectra 386-25 (IBM compatible). Survival was estimated by
the method of Kaplan-Meier and differences between curves
were tested for statistical significance with the log-rank test.
Multivariate analysis of the main clinical and histological
parameters (P-values in the univariate analysis < 0.10) was
performed using the Cox proportional hazard method in a
stepwise manner.
Results
Univariate analysis of histological parameters showed that
only the presence of microcalcifications was statistically
associated with prolonged survival (P = 0.03); the presence of
microcysts showed a similar trend but did not reach statis-
tical significance (P = 0.1). Multivariate statistical analysis of
the clinical and histological parameters with the Cox propor-
tional hazards model demonstrated that preoperative Kar-
nofsky score and the extent of surgery were by far the most
important variables in predicting length of survival
(P = 0.0001 and P = 0.0007 respectively in univariate
analysis, see Table I; the results of multivariate analysis are
reported in Table II), whereas no histological parameter
provided statistically significant prognostic information.
p53 immunolabelling was not observed in normal nervous
tissue adjacent to the tumours, as previously reported by us
(Barbareschi et al., 1992a). p53 immunostaining was detected
in nuclei in 32 out of 52 tumours (61.5%) (Figure 1). pS3LI
ranged from 0.1% to 40%. Eight cases (15.4%) with only
rare positive cells (less than 1% of the cells) were considered
negative for p53 accumulation (see Table III). Heterogeneous
distribution of p53-immunoreactive cells was frequently seen,
especially in tumours with high pS3LI. The intensity of
nuclear labelling within the tumours also varied: lesser or
more intensely immunoreactive nuclei were randomly interm-
ingled.
The clinical data of the groups of p53-positive and p53-
negative patients are shown in Tables IV and V. Age, com-
pleteness of surgical resection, Karnofsky status and site of
the tumours were similarly distributed in the two groups of
patients.
Median survival for p53-positive and p53-negative patients
was 41 and 37 months respectively. The survival curves of
p53-positive and -negative patients are shown in Figure 2.
The curves do not show statistically significant differences.
Similar results were also obtained when we subdivided the
cases in three groups, i.e. negative, low positive with pS3LI
>1 and <10%, and highly positive with pS3LI > 10%
(Figure 3).
Although there are no statistically significant differences in
survival between p53-positive and -negative tumours, the
curves show a trend towards a more aggressive course in
p53-positive patients 4 years after surgery, where the curves
diverge. In fact, 5 years after diagnosis the survival estimate
with the Kaplan-Meier method is only 21.2% for patients
with p53-positive tumours, while at the same time the
estimated survival for patients with p53-negative tumours is
45.9%. However the small number of patients alive after 5
years does not allow valid separate analysis.
In five patients recurrences were surgically removed: one
case was an anaplastic astrocytoma and the others glioblas-
tomas. The recurrences derived from four p53-positive
tumours (mean pS3LI 5%, range 3-13%) and one neoplasm
with only occasional p53-positive cells (pS3LI = 0.1%). All
recurrent tumours were themselves p53 positive, with high
pS3LI (mean pS3LI 55%, range 20-90%).
Discussion
This study demonstrates that histological parameters are of
little value in predicting the outcome of patients suffering
from low-grade astrocytomas, highlighting the need for addi-
tional biological parameters to improve outcome prediction
in this group of patients.
In the present series of low-grade astrocytomas we show
p53 immunoreactivity in 46% of patients with wide range of
percentage of nuclear staining. No statistically significant
differences in survival curves were observed between p53-
positive and p53-negative patients. However p53-positive
patients showed a trend towards worse prognosis.
p53 gene mutation and p53 protein accumulation have
been documented in low- and high-grade astrocytomas, and
it has been suggested that p53 mutation occurs in the initial
stages of tumour formation (Ellison et al., 1992; von Deim-
ling et al., 1992, 1993; Louis et al., 1993). This is in keeping
with the demonstration that loss of heterozygosity for loci on
the short arm of chromosome 17 (17p) (where the p53 gene is
located) is shared by cells in each malignancy stage (El-
Azouzi et al., 1989; James et al., 1989, 1990; Bigner &
Vogelstein, 1990; Venter & Thomas, 1991; Cavenee, 1992;
von Diemling et al., 1993). p53 gene and protein alterations
could indeed be an early event in tumour progression, which
may be associated with clinical aggressiveness. It might
therefore be hypothesised that p53 protein accumulation588 P. IUZZOLINO et al.
Table I Results of univariate analysis
Nwnber Log-rank test'
Factor of cases Chi-square df. p-value
Age (years) 66 9.16 1 0.0025
Sex
Male
Female
Duration of
symptoms (months)
Neurological deficit on
admission
Endocranial hypertension
Epilepsia
Neurological or cognitive
deficit
More than one symptom
Preoperative
performance status
100-80
70-50
40-10
Post-operative
performance status
100-80
70-50
40-10
Time from diagnosis
to treatment (months)
Extent of surgery
Total
Partial
Radiotherapy
(three missing values)
Not done
Done
Histological type
Fibrillary
Protoplasmic
Cellular density
Low
High
Nuclear pleomorphism
(two missing valuesb)
Slight
Moderate
Mitotic activity
(two missing values)
0
<0.9x 10HPF
Vessels frequency
(two missing values)
Normal
Increased
Microcysts
(two missing values)
Present
Absent
Microcalcifications
Present
Absent
p53
Negative ( < 1%)
Positive (>1%)
32
34
66
0.74
0.03
12
30
6
18
22
31
13
39
19
8
66
0.03
20.64
4.72
6.33
12
54
16
47
24
42
61
3
31
33
48
16
11
53
40
24
12
52
28
24
11.48
2.31
0.01
0.39
0.86
3 0.99
2 0.0001
2 0.09
1 0.01
1 0.0007
1 0.13
1 0.13
No test performed
0.61
0.47
2.16
1 0.44
1 0.49
1 0.14
2.79 1 0.10
4.49
1.42
1 0.03
1 0.23
aSignificance ofcovariates was tested using a generalised form of the log-rank
test (score test). bThe missing values are the two pleomorphic
xanthoastrocytomas.
Table H Results of the multivariate analysis on clinical, therapeutic and histological
parameters
Regression Standard Wald Pr> Risk ratio
Variables (CI) error chi-square chi-square (CI)
Extent of surgery 1.51 0.61 6.08 0.0137 4.53
(partial/total) (0.30-2.71) (1.36-15.03)
Karnofsky - 1.42 0.44 10.19 0.0014 0.24
(high/low) (-2.28 to - 0.56) (0.10-0.57)
Karnofsky - 1.04 0.38 7.53 0.0061 0.35
(medium/low) (-1.78 to - 0.30) (0.17-0.74)
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could be a significant prognostic indicator in low-grade astro,-
cytic tumours. In fact Jaros et a!. (1 992) showed that in a
series of 43 astrocytomas (ten low grade and 33 high grade)
p53 protein overaccumulation was associated with reduced
survival (P <0.035 in univariate analysis). However, in their
study survival was analysed in the whole series of astrocytic
tumours without separating low- and high-grade lesions.
Hence differences in survival probably reflect the effect of
different histopathological patterns, high-grade astrocytomas
being more frequently p5-3 positive than low-grade tumours.
In our series the bias due to different histopathological char-
acteristics should be negligible, all cases being selected on the
basis of low-grade histological picture as determined on
large, representative surgical samples. In our series we could
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Figure 2 Survival curves for the 52 patients with supratentorial
low-grade astrocytomas based upon the accumulation of p53
protein. Patients are subdivided in two groups, with and without
p53 protein accumulation. The solid line represents the 28
patients with pS3LI < 1, while the dashed line represents the 24
patients with pS3LI> 1. The log-rank test for comparing survival
curves gives a non-significant result (P
= 0.23).
Figure 1 p53 immunoreactivity in low-grade astrocytoma. Reac-
tive nuclei are marked with arrows. Original magnification 400 x,
D07 p53 immunostaining with light haematoxylin counter-
stain.
Table HII p53 expression in low-grade astrocytomas
pS3LI
No. of cases Mean () Range()
Negative for p53 accumulation
20 (38.5%) -
8 (15.4%) 0 0.1-1
Positive for p53 accumulation
15 (28.8%) 4.9 2-8
9 (17.3%) 20.8 11-40
Total 52 (100%)
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Figure 3 Survival curves for the 52 patients with supratentorial
low-grade astrocytomas based upon the accumulation of p53
protein. Patients are subdivided in three groups: p53-positive, low
p53-positive, highly p53-positive. The solid line represents the 28
patients with pS3LI < 1, the dashed line represents the 15 patients
with pS3LI between >1I and $< 10 and the semi-dashed line the
nine patients with pS3LI> 10. The log-rank test for comparing
survival curves gives a non-significant result (P
= 0.49).
Table IV Clinical data regarding p53-positive and -negative cases
Age (years) Radical Karnofsky score"
(mean ± s.d.) Range surgery High Medium Low
p53-positive cases 38.6 ± 12.2 16-74 12.5% 33.3% 37.5% 29.2%
p53-negative cases 37.5 ± 13.2 19-70 15.4% 35.7% 42.9% 21.4%
'Karnofsky scores are defined as follows: 100-80= high, 70-50 = medium, <50=low (Karnofsky &
Burchenl, 1949).
Table V Anatomical site of p53-positive and -negative tumours
Corpus callosum
Frontal Rolandic Parietal Temporal and basal nuclei
p53-positive 9 0 3 8 4
p53-negative 3 3 7 8 7
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not find a statistically significant difference between the sur-
vival of p53-positive and p53-negative patients. However,
3-4 years after surgical intervention and diagnosis the sur-
vival curves showed a trend towards a shorter survival for
p53-positive patients. The trend for a more aggressive course
in p53-positive patients is even more evident considering that
at 5 years follow-up the survival estimate with the Kaplan-
Meier method is only 21.2% for patients with p53-positive
tumours, while at the same time the estimated survival for
patients with p53-negative tumours is 45.9%. It is unlikely
that this trend is due to factors such as age, incomplete
resection, Karnofsky status or site of the tumours, since there
were no major differences in the above parameters in the two
groups of patients.
The fact that the trend is not apparent until 3-4 years
follow-up could be interpreted as being a consequence of the
time needed for the p53-positive subclone to outgrow the rest
of the p53-negative neoplastic cell population. The long time
needed for the p53-positive subclone to overgrow the other
cells could be related to the low proliferative activity of
low-grade astrocytomas (Giangaspero et al., 1987; Hoshino
et al., 1988; Allegranza et al., 1991).
The hypothesis of the clonal expansion of the p53-positive
neoplastic cells is further supported by the fact that all five
patients in our series in whom we could examine a recurrent
tumour were at least focally p53-positive and the recurrent
tumours were themselves intensely p53 positive, with a pS3LI
more than ten times higher than the primitive neoplasms.
These recurrent tumours could be the expression of the
clonal expansion of the pre-existing p53-positive clones, in
keeping with the hypothesis of Sidransky et al. (1992).
The fact that the recurrent tumours that we could analyse
were histologically malignant (one grade III astrocytoma and
four glioblastomas) could be related to the fact that, once a
tumour is composed mainly of a p53-positive genetically
unstable cell population (Lane, 1992), the likelihood of fur-
ther genetic damage is greater and specific additional struc-
tural changes, for example on chromosome 10, could be
more frequent, leading to the development of a highly ag-
gressive tumour (Bigner & Vogelstein, 1990; von Diemling et
al., 1993). In this view the four recurrences with histological
features of glioblastomas could be interpreted as type 1
glioblastomas according to von Diemling et al. (1993).
The present study thus suggests the following conclusions:
(1) p53 protein accumulation in the nuclei of low-grade
astrocytomas is a frequent event (more than 40% ofcases are
positive). (2) p53 accumulation is not associated with statisti-
cally significant differences in survival, despite a trend for
p53-positive tumours to be more aggressive. (3) The trend for
a more aggressive course is apparent after a latency period of
3-4 years from diagnosis, which could be related to the time
needed by the p53-positive clone to expand; this fact was
further supported by widespread p53 positivity observed in
recurrences.
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